Int. Rev. Allergol. Clin. Immunol. Family Med., 2020, XXVI/2: 055-060 Maximize

Int. Rev. Allergol. Clin. Immunol. Family Med., 2020, XXVI/2: 055-060

Title: Who is most at risk of developing COVID-19? 

Author: Płusa T. 

More details


40,00 zł


Who is most at risk of developing COVID-19?

Płusa T.

Medical Faculty of Lazarski University, Warsaw, Poland

International Review of Medical Practice, 2020; Vol. 26, No. 2, 055

The COVID-19 mortality rate specified by the Chinese Center for Disease Control and Prevention is 2.3% and the incidence rate is 10.5%, depending on the region. Comorbidities and all types of immune deficiencies were suggested as responsible for increased mortality. The potential role in the development of COVID-19 the angiotensin converting enzyme 2 (ACE-2), which is a surface receptor in most human cells and participates in the first phase of infection, binding the protein S of the glycoprotein spike SARSCoV- 2 was also pointed out. The analyzes of COVID-19 patients from 169 hospitals over the world the impact of the age of patients on the disease, expressed as a mortality rate of 10.0% in the group of patients over 65 years of age compared to 4.9% in the younger group. It was also shown that Caucasian patients were the most likely to die, and women were less likely to be ill than men. Among those who died in COVID-19, hyperlipidemia was found in 35.0%, hypertension in 25.2%, coronary heart disease in 20.0%, diabetes in 18.8%, and 16.1% of smoking in the past. It has not been confirmed that ACE inhibitors and angiotensin receptor blockers (ARBs) increase the risk of illness and death in patients with COVID-19. Another study documented the usefulness of administering glycopyronium, formoterol and budesonide in inhibiting coronavirus replication in nasal and tracheal epithelial cells, indicating their protective efficacy against SARS-CoV-19 infection in patients with chronic obstructive lubg diseases. In current world statistics, Poland ranks 31th in terms of the number of COVID-19 patients.

Key words: COVID-19, comorbidities, mortality, risk of illness